Last checked at 12 Nov 2015 14:45
12 November 2015 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or "the Company")
Notification of Interim Results
Guildford, UK, 12 November 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will announce its interim results for the six months ended 30 September 2015 on Monday 7 December 2015.
A meeting for analysts will be held at 9.30am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am on the day of the results: http://vm.buchanan.uk.com/2015/reneuron071215/registration.htm
A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com
Enquiries:
ReNeuron | +44 (0) 1483 302560 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan |
+44 (0) 20 7466 5000 |
Mark Court, Sophie Cowles, Stephanie Watson | |
Cenkos Securities | +44 (0) 20 7397 8900 |
Stephen Keys, Dr Christopher Golden (NOMAD and Broker) | |
Russell Kerr (Sales) |
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US.
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.